TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Targeted agents have already been approved for use in PTCL, with brentuximab vedotin now established as a clear standard in the primary treatment of CD30-positive PTCL based on the randomized ECHELON-2 clinical trial5.